Primary Antibody Global Market Report 2025

The primary antibody market size has grown strongly in recent years. It will grow from $42.1 billion in 2024 to $45.78 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising use of immunoassays in biomedical research, increasing incidence of chronic and infectious diseases, growing applications in proteomics and genomics, increasing collaborations among academic and research institutions, and rising utilization of antibodies in diagnostic assays.

The primary antibody market size is expected to see strong growth in the next few years. It will grow to $63.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising focus on biomarker based research, expansion of clinical and translational research programs, growing investments in life sciences and biotechnology, and increasing automation in antibody development and testing. Major trends in the forecast period include technological advancements in antibody engineering, developments in recombinant antibody production, investment in research and development for high throughput screening methods, innovations in antibody labeling and detection technologies, and technological progress in multiplex immunoassay platforms.

The increasing adoption of immunodiagnostics is expected to drive the growth of the primary antibody market in the coming years. Immunodiagnostics refers to diagnostic methods that utilize antigen-antibody reactions to detect and quantify specific biomolecules linked to infections, autoimmune diseases, and cancers. Adoption is rising as healthcare systems and laboratories seek more accurate, rapid, and reliable methods of disease detection to enhance clinical decision-making and patient outcomes. Primary antibodies support immunodiagnostic assays by specifically binding to target antigens, enabling precise detection and analysis of proteins, pathogens, or biomarkers. They improve diagnostic accuracy and reliability, reduce errors in experimental and clinical testing, and are essential in techniques such as ELISA, Western blotting, and immunofluorescence. For example, in November 2024, according to the UK Health Security Agency, a UK based government agency, between April 2022 and March 2024, a total of 1,981,590 HIV tests, 1,502,799 HCV tests, and 1,185,678 HBV tests were conducted. Therefore, the growing adoption of immunodiagnostics is driving the expansion of the primary antibody market.

Major companies in the primary antibody market are developing innovative products such as mutation-specific antibodies to improve diagnostic accuracy, enhance workflow efficiency, and reduce the risk of misdiagnosis. A mutation-specific antibody is designed to bind selectively to a defined antigen variant rather than a broad native antigen population, enabling clinicians to target specific protein mutations with high precision. For example, in February 2023, F. Hoffmann-La Roche AG, a Switzerland based diagnostics and pharmaceutical company, launched the IDH1 R132H (MRQ 67) rabbit monoclonal primary antibody and the ATRX rabbit polyclonal antibody. These products offer high specificity for the IDH1 R132H mutation, are compatible with the BenchMark IHC/ISH platform, and support automated workflows for neuropathology. These antibodies enhance diagnostic precision and workflow efficiency while requiring higher development costs and having narrower target applicability.

In December 2023, Danaher Corporation, a US based biotechnology company, acquired Abcam plc for $5.7 billion. Through this acquisition, Danaher aims to strengthen its position in the life sciences and proteomics market, expanding its portfolio of research reagents, antibodies, and related solutions for drug discovery and diagnostics. Abcam plc is a UK based life sciences company providing primary antibodies for immunology and cancer research.

Major companies operating in the primary antibody market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Danaher Corporation, Johnson & Johnson Services Inc., Fujifilm Holdings Corporation, Agilent Technologies Inc., Becton Dickinson And Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Genscript Biotech Corporation, Biocytogen Co. Ltd., Sino Biological Inc., Cell Signaling Technology Inc., Cusabio Biotech Co. Ltd., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Creative Diagnostics Inc., Abnova Corporation, Promab Biotechnologies Inc., Boster Biological Technology Co. Ltd., Biorbyt Ltd., Capralogics Inc.

North America was the largest region in the primary antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the primary antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The primary antibody market research report is one of a series of new reports that provides primary antibody market statistics, including primary antibody industry global market size, regional shares, competitors with a primary antibody market share, detailed primary antibody market segments, market trends and opportunities, and any further data you may need to thrive in the primary antibody industry. This primary antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A primary antibody is an immunoglobulin molecule specifically designed or naturally produced by the immune system to bind directly and with high affinity to a defined antigenic epitope, enabling selective identification, quantification, or neutralization of a target molecule in a biological sample or experimental system. It is widely used in immunoassays, molecular diagnostics, and biomedical research to detect or measure specific proteins or biomolecular targets with accuracy and reliability.

The main types of primary antibody include primary antibodies, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), other isotypes, and secondary antibodies. Primary antibodies are highly specific immunoglobulin molecules that bind directly to target antigens to allow detection, measurement, or characterization of specific proteins or biomolecules in research, diagnostic, or therapeutic settings. They are sourced from monoclonal antibodies, polyclonal antibodies, and recombinant antibodies and use technologies such as enzyme linked immunosorbent assay (ELISA), western blotting, immunohistochemistry, and flow cytometry. They are applied in research and development, diagnostics, in vitro diagnostics, point of care testing, and therapeutics, serving end users such as academic and research institutions, pharmaceutical and biopharmaceutical companies, clinical laboratories, and contract research organizations (CROs).

The primary antibody market consists of sales of antibody reagents, assay kits, detection reagents, antigen-specific probes, and labeling conjugates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.